All In Biotech

Drug Trial Radar · NCT02170870

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Apr 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Jun 2014

Primary completion

Nov 17, 2017

Study completion Nov 17, 2017

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Jun 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand why people with indigestion have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine and to a hormone (GLP1) which is normally released from the small intestine in response to nutrients. We propose to study the contribution of GLP1 to intestinal sensitivity with a drug (exendin 9-39) that blocks the effects of GLP1.

Conditions

  • Dyspepsia
  • Diabetes Mellitus With Gastrointestinal Symptoms

Interventions

  • Exendin 9-39Drug

    Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).

  • MicrolipidDrug

    Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).

  • PlaceboDrug

    Normal saline infusion will be prepared to match the appearance of Exendin 9-39

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Intestinal Chemosensitivity to Lipids PerfusionTime frame: Day 1, approximately 2 hours after infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.